- Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, subject and investigator blinded, placebo controlled and multi-center platform study, to assess efficacy and safety of different investigational drugs in patients with moderate to severe hidradenitis suppurativa
This study is testing new medicines for people with moderate to severe hidradenitis suppurativa, a skin condition. Researchers want to see if the new medicines can improve symptoms and are safe, compared to a dummy treatment.
For: Moderate to severe hidradenitis suppurativaHungary · Austria · Germany - Active not recruitingPHASE3
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
This study is testing a new medicine, ianalumab, for people with active Sjögren's syndrome. Researchers want to see if it's safe and helps improve symptoms. Participants will receive either the new medicine or a dummy medicine called a placebo.
For: Sjogren SyndromeUnited States · Argentina · Australia - Ongoing, recruitingPhase II and Phase III (Integrated)
A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER)
This study is looking into a new treatment, VAY736, for adults with a liver condition called autoimmune hepatitis. It aims to see if VAY736 is safe and helps improve liver blood tests for people whose current treatments aren't working well or cause side effects.
For: Autoimmune hepatitisCzechia · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
An open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome
This study is looking at a new medicine called ianalumab for Sjögren's syndrome. We want to see how it affects cells in the salivary glands, how safe it is, and how the body uses it. This is an early-stage study.
For: Sjögren's syndromeFrance - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo controlled, 2-armmulticenter phase 3 study to assess the efficacy and safetyof ianalumab in patients with active Sjögren’s syndrome(NEPTUNUS-1)
This study is testing a new medicine, ianalumab, for adults with active Sjögren’s syndrome. It compares the new medicine to a dummy medicine (placebo) to see if it helps reduce symptoms and improve quality of life.
For: Sjögren’s SyndromeBelgium · Czechia · Spain - AuthorisedTherapeutic exploratory (Phase II)
Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT)
This study looks at a medicine called ianalumab for adults with certain blood conditions (ITP or wAIHA). It wants to see if the medicine continues to work well for those who have used it before, aiming to understand its long-term benefits.
For: Immune thrombocytopenia (ITP) Warm autoimmune hemolytic anemia (wAIHA)Germany · Czechia · Belgium